Literature DB >> 18941116

Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Massimo Alfano1, Samanta A Mariani, Chiara Elia, Ruggero Pardi, Francesco Blasi, Guido Poli.   

Abstract

Urokinase-type plasminogen activator (uPA) signaling via its receptor uPAR inhibits late events in HIV-1 replication in acutely infected primary monocyte-derived macrophages (MDMs) and promonocytic U937 cells. Here we show that U937-derived, chronically infected U1 cells stimulated with phorbol 12-myristate 13-acetate (PMA) express integrins, uPA, and soluble uPAR at levels similar to those of MDMs. uPA inhibited HIV expression in U1 cells incubated with either PMA or tumor necrosis factor-alpha (TNF-alpha), but not with other HIV-inductive cytokines or lipopolysaccharide. Of interest, only PMA and TNF-alpha, but not other HIV-inductive stimuli, induced surface expression of the alpha(M) chain CD11b in U1 cells constitutively expressing CD18, the beta(2) chain of the Mac-1 integrin. Like uPA, fibrinogen, a Mac-1 (CD11b/CD18) ligand, and M25, a peptide homologous to a portion of the beta-propeller region of CD11b preventing its association with uPAR, inhibited HIV virion release in PMA-stimulated U1 cells. Both uPAR small-interference RNA (siRNA) and soluble anti-beta(1)/-beta(2) monoclonal antibodies abolished the anti-HIV effects of uPA, whereas CD11b siRNA reversed the anti-HIV effect of M25, but not that induced by uPA. Thus, either uPA/uPAR interaction, Mac-1 activation, or prevention of its association with uPAR triggers a signaling pathway leading to the inefficient release of HIV from monocytic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941116      PMCID: PMC2647677          DOI: 10.1182/blood-2008-02-138412

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

Review 1.  Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence.

Authors:  Edana Cassol; Massimo Alfano; Priscilla Biswas; Guido Poli
Journal:  J Leukoc Biol       Date:  2006-08-31       Impact factor: 4.962

2.  Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients.

Authors:  B Sporer; U Koedel; B Popp; R Paul; H-W Pfister
Journal:  J Neuroimmunol       Date:  2005-04-13       Impact factor: 3.478

Review 3.  Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection.

Authors:  Clare L V Maslin; Katherine Kedzierska; Nicole L Webster; William A Muller; Suzanne M Crowe
Journal:  Curr HIV Res       Date:  2005-10       Impact factor: 1.581

4.  Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.

Authors:  S R Ostrowski; T L Katzenstein; M Pedersen; G Høyer-Hansen; J Gerstoft; B K Pedersen; H Ullum
Journal:  Scand J Immunol       Date:  2006-06       Impact factor: 3.487

Review 5.  uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.

Authors:  Bernd R Binder; Judit Mihaly; Gerald W Prager
Journal:  Thromb Haemost       Date:  2007-03       Impact factor: 5.249

6.  Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor.

Authors:  Nelli Shushakova; Natalia Tkachuk; Marc Dangers; Sergey Tkachuk; Joon-Keun Park; Joerg Zwirner; Koji Hashimoto; Hermann Haller; Inna Dumler
Journal:  J Cell Sci       Date:  2005-06-15       Impact factor: 5.285

Review 7.  Float on: lipid rafts in the lifecycle of HIV.

Authors:  Doris Wilflingseder; Heribert Stoiber
Journal:  Front Biosci       Date:  2007-01-01

8.  Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.

Authors:  Nicolai Sidenius; Manuela Nebuloni; Stefania Sala; Pietro Zerbi; Richard W Price; Magnus Gisslen; Lars Hagberg; Luca Vago; Adriano Lazzarin; Francesco Blasi; Paola Cinque
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

9.  Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1.

Authors:  Chiara Rizzi; Massimo P Crippa; Rienk E Jeeninga; Ben Berkhout; Francesco Blasi; Guido Poli; Massimo Alfano
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

10.  Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.

Authors:  Gillian E Stillfried; Darren N Saunders; Marie Ranson
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  7 in total

Review 1.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

Review 2.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

3.  Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix.

Authors:  Luca Genovese; Lidia Zawada; Antonella Tosoni; Angelita Ferri; Pietro Zerbi; Raffaele Allevi; Manuela Nebuloni; Massimo Alfano
Journal:  Tissue Eng Part A       Date:  2014-03-06       Impact factor: 3.845

4.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 5.  Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Authors:  Daniela Alfano; Paola Franco; Maria Patrizia Stoppelli
Journal:  Front Cell Dev Biol       Date:  2022-04-08

6.  ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.

Authors:  Xinyuan Cui; Xiaosong Pei; Hao Wang; Ping Feng; Huamin Qin; Shuai Liu; Qiu Yan; Jiwei Liu
Journal:  Cells       Date:  2022-10-06       Impact factor: 7.666

7.  HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.

Authors:  Manuela Nebuloni; Lidia Zawada; Angelita Ferri; Antonella Tosoni; Pietro Zerbi; Massimo Resnati; Guido Poli; Luca Genovese; Massimo Alfano
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.